ArticleOphthalmology and therapy2026
Experts Perspectives on Current Practices and Challenges of Diagnosis and Treatment of Dry Eye Disease across Europe and Central Asia.
Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDry eye disease (DED) is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiological roles. Affecting up to 60% of individuals worldwide, DED imposes a significant physical, psychosocial, and economic burden. Its diagnosis remains challenging owing to heterogeneous clinical presentations, poor correlation between signs and symptoms, and limited access to advanced diagnostic tools. This study aimed at exploring real-world clinical practices in the diagnosis and management of DED across Europe and Central Asia by gathering experts' perspectives.
methodsA panel of experts comprising 15 specialists from tertiary referral centers across 10 countries convened to discuss diagnostic workflows and treatment strategies for DED.
resultsThe consensus emphasized that symptom questionnaires, slit-lamp examination, tear break-up time, and corneal and conjunctival staining represent the cornerstone of diagnosis. Tear osmolarity testing was used less frequently, primarily owing to cost and limited resource availability. Most cases managed in specialized centers were moderate-to-severe, underscoring the need for comprehensive and multidisciplinary evaluation. Treatment practices emphasized a stepwise approach, with first-line therapy comprising conventional measures such as environmental and behavioral modifications, tear substitutes, and lid hygiene. Cyclosporine A (CsA) eye drops were reserved for patients with an insufficient response to first-line therapy or with clinically significant ocular surface inflammation. In these cases, experts indicated that concomitant short-term glucocorticosteroids with CsA may be used initially, followed by CsA monotherapy for long-term disease control. Regular follow-up and patient education were considered essential to support treatment adherence and efficacy. Interdisciplinary collaboration, particularly with rheumatologists and mental health professionals, was regarded as critical for managing systemic comorbidities and addressing psychosocial impacts.
conclusionsThis consensus highlights the value of sharing experts' experience to harmonize care standards and optimize clinical outcomes. Early recognition of ocular surface inflammation, timely initiation of immunomodulatory therapy, and integrated multidisciplinary care are essential for improving patient quality of life across diverse healthcare settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.